

Marie-Claude Bourgeois-Daigneault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6745827/publications.pdf>

Version: 2024-02-01

28
papers

1,785
citations

516710

16
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

3444
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncolytic viruses for antigen delivery. , 2022, , 1-19.		0
2	In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity. , 2021, 9, e001387.		26
3	Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nature Communications, 2021, 12, 2626.	12.8	32
4	The pros and cons of interferons for oncolytic virotherapy. Cytokine and Growth Factor Reviews, 2020, 56, 49-58.	7.2	19
5	Magnetic targeting of oncolytic VSV-based therapies improves infection of tumor cells in the presence of virus-specific neutralizing antibodies in vitro. Biochemical and Biophysical Research Communications, 2020, 526, 641-646.	2.1	9
6	Pre-surgical oncolytic virotherapy improves breast cancer outcomes. OncoImmunology, 2019, 8, e1655363.	4.6	4
7	Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer. Scientific Reports, 2019, 9, 1865.	3.3	21
8	Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. Cancer Research, 2018, 78, 922-937.	0.9	46
9	Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice. Journal of Immunotherapy, 2018, 41, 125-129.	2.4	16
10	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Science Translational Medicine, 2018, 10, .	12.4	242
11	Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference. , 2018, 6, 62.		8
12	Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. Journal of Clinical Investigation, 2018, 128, 4654-4668.	8.2	591
13	Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation. OncoImmunology, 2017, 6, e1285992.	4.6	60
14	MARCH1 E3 Ubiquitin Ligase Dampens the Innate Inflammatory Response by Modulating Monocyte Functions in Mice. Journal of Immunology, 2017, 198, 852-861.	0.8	29
15	Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines, 2017, 5, 3.	3.2	29
16	Oncolytic vesicular stomatitis virus expressing interferon- γ has enhanced therapeutic activity. Molecular Therapy - Oncolytics, 2016, 3, 16001.	4.4	63
17	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular Therapy - Oncolytics, 2016, 3, 16027.	4.4	11
18	Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR Journal, 2016, 57, 73-85.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Combination of Paclitaxel and MC1 oncolytic virus as a successful strategy for breast cancer treatment. Breast Cancer Research, 2016, 18, 83.	5.0	73
20	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell, 2015, 28, 210-224.	16.8	77
21	Identification of a novel motif that affects the conformation and activity of the MARCH1 E3 ubiquitin ligase. Journal of Cell Science, 2013, 126, 989-98.	2.0	11
22	Tollip-induced down-regulation of MARCH1. Results in Immunology, 2013, 3, 17-25.	2.2	13
23	Major histocompatibility complex class-II molecules promote targeting of human immunodeficiency virus type 1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane. Cellular Microbiology, 2013, 15, 809-822.	2.1	5
24	Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. OncoImmunology, 2012, 1, 908-916.	4.6	135
25	Autoregulation of MARCH1 Expression by Dimerization and Autoubiquitination. Journal of Immunology, 2012, 188, 4959-4970.	0.8	41
26	Cutting Edge: HLA-DO Impairs the Incorporation of HLA-DM into Exosomes. Journal of Immunology, 2011, 187, 1547-1551.	0.8	18
27	Sorting of MHC Class II Molecules into Exosomes through a Ubiquitin-Independent Pathway. Traffic, 2009, 10, 1518-1527.	2.7	61
28	Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. European Journal of Immunology, 2008, 38, 1225-1230.	2.9	135